Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

When my bipolar depression returned, I mistakenly began to wean off a medication, not considering how it helped ease my other ...

This group of international experts in the treatment of bipolar disorder was convened in New York in December 2003. As a departure point for their discussions, it was noted that the treatment of ...

Study published in Nature identifies nearly 300 genomic regions associated with bipolar disorder, and 36 key genes involved in the disease. The biological insights from this research could pave the ...

In a study derived from a questionnaire distributed to patients with bipolar disorder who are members of the Depression and Bipolar Support Alliance (DBSA), Hirschfeld and colleagues [18] reported ...

selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipolar depression and will ...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that on January 17, 2025, it received written notice from the Nasdaq ...

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced ...

Premenstrual dysphoric disorder (PMDD) and bipolar disorder are separate conditions, but they share significant overlap in mood-related symptoms. Research suggests that people living with bipolar ...